Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant CCR4 (Mogamulizumab Biosimilar) antibody

The Rabbit Chimeric anti-CCR4 (Mogamulizumab Biosimilar) antibody is suitable to detect CCR4 (Mogamulizumab Biosimilar) in samples from Human. It has been validated for Dep.
Catalog No. ABIN7072382
$624.00
Plus shipping costs $50.00
200 μg
Shipping to: United States
Delivery in 7 to 13 Business Days

Quick Overview for Recombinant CCR4 (Mogamulizumab Biosimilar) antibody (ABIN7072382)

Target

CCR4 (Mogamulizumab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 5
  • 1
  • 1
Rabbit

Clonality

  • 5
  • 2
Chimeric

Conjugate

  • 5
  • 1
  • 1
This CCR4 (Mogamulizumab Biosimilar) antibody is un-conjugated

Application

  • 5
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
Depletion (Dep)

Clone

KW-0761
  • Purpose

    Anti-CCR4 [KW-0761 (Mogamulizumab)], Rabbit IgG, kappa

    Specificity

    This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.

    Application Notes original Clone: The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8 % and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action, in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.

    Characteristics

    This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    Purification

    Protein A affinity purified

    Immunogen

    This antibody was prepared by humanization of a mouse anti-CCR4 mAb.

    Isotype

    IgG, kappa
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Comment

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Restrictions

    For Research Use only
  • Concentration

    1 mg/mL

    Buffer

    PBS with 0.02 % Proclin 300.

    Preservative

    ProClin

    Precaution of Use

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C,-20 °C

    Storage Comment

    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target

    CCR4 (Mogamulizumab Biosimilar)

    Target Type

    Biosimilar

    Background

    CD194, CKR-4, CCR-4, CCR4, K5-5

    UniProt

    P51679
You are here:
Chat with us!